SCHEMBL697597

SCHEMBL697597

CS(=O)(=O)N1CCCC1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.50
ALDH1A1 P00352 3/20 0.46
HTT P42858 1/20 0.46
MMP8 P22894 1/20 0.46
MMP12 P39900 1/20 0.46
MMP13 P45452 1/20 0.46
HSD17B10 Q99714 3/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 3/20 0.42
ACE P12821 4/20 0.41
REN P00797 2/20 0.41
CYP2C19 P33261 1/20 0.41
F2 P00734 1/20 0.41
LTA4H P09960 1/20 0.41
MAPT P10636 1/20 0.41
PEPD P12955 1/20 0.41
ALOX15 P16050 1/20 0.41
PTGS1 P23219 1/20 0.41
HTR2A P28223 1/20 0.41
PTGS2 P35354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3153775 1.00 POLB (0.50) POLBALDH1A1HTTMMP8MMP12
SCHEMBL697598 1.00 POLB (0.50) POLBALDH1A1HTTMMP8MMP12
SCHEMBL17327498 0.94 ALDH1A1 (0.53) POLBALDH1A1HTTMMP8MMP12
SCHEMBL17327496 0.94 ALDH1A1 (0.53) POLBALDH1A1HTTMMP8MMP12
SCHEMBL14594697 0.94 ALDH1A1 (0.53) POLBALDH1A1HTTMMP8MMP12
SCHEMBL17327489 0.89 ALDH1A1 (0.41) POLBALDH1A1HTTMMP8MMP12
SCHEMBL15746879 0.83 TSHR (0.37) POLBALDH1A1HTTKDM4E
SCHEMBL16886885 0.82 PLAU (0.36) POLBALDH1A1KDM4E
SCHEMBL16886888 0.82 PLAU (0.36) POLBALDH1A1KDM4E
SCHEMBL3068881 0.82 PER2 (0.38) POLBALDH1A1MMP8MMP12MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1451 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055449-A Class 2V-type CRISPR-Cas lead editing 巴斯夫农业解决方案美国有限责任公司 2026-05-15 CN claimed
CN-120060241-B Base editor ACGBEmax for simultaneously realizing substitution of purine and pyrimidine 中国农业大学 2026-05-15 CN claimed
CN-122012476-A Difunctional deaminase with adenine and cytosine bidirectional deamination activity, mutant thereof, screening method and application 深圳湾实验室 2026-05-12 CN claimed
CN-122012441-A Herbicide resistance mutant of AhALS gene and application of herbicide resistance mutant in peanut breeding 河南省农业科学院 2026-05-12 CN claimed
EP-4615416-A1 SELF-ASSEMBLING LIPID NANOPARTICLES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS Ramot at Tel-Aviv University Ltd. (IL) 2025-09-17 EP claimed
CN-120041417-A Sites linked with GBSS I protease activity and amylose synthesis and application thereof 扬州大学 2025-05-27 CN claimed
CN-120005859-A Compositions and methods for treating heme lesions 比姆医疗股份有限公司 2025-05-16 CN claimed
CN-115992122-B Cytosine base editor based on modified APOBEC3A of people 江南大学 2025-05-16 CN claimed
CN-115992124-B Cytosine base editor based on cynomolgus monkey APOBEC3A and mutant thereof 江南大学 2025-05-13 CN claimed
CN-119955812-A Breeding method and application for improving corn biomass and kernel yield through site-directed base mutation of corn ZmGRF1 gene 中国农业科学院作物科学研究所 2025-05-09 CN claimed
CN-110880054-B Planning method for electric network car-booking charging and battery-swapping path 国网四川省电力公司天府新区供电公司 2022-05-20 CN claimed
WO-2022100662-A1 GENOMIC EDITING OF IMPROVED EFFICIENCY AND ACCURACY SHANGHAITECH UNIVERSITY (CN) 2022-05-19 WO claimed
EP-3994257-A2 HOST SYSTEMS COMPRISING INHIBITORS OF A GENE-EDITING PROTEIN FOR PRODUCTION OF VIRAL VECTORS Asklepios Biopharmaceutical, Inc. (US) 2022-05-11 EP claimed
CN-114437113-A Thiazolopyridine ring-linked triazole compound and preparation method and application thereof 西安交通大学 2022-05-06 CN claimed
CN-112539722-B Method for measuring key machining error of double-crank cycloid wheel of speed reducer for robot 华北水利水电大学 2022-05-06 CN claimed
US-20220127622-A1 Compositions and Methods for Improving Base Editing BEAM THERAPEUTICS INC. (US) 2022-04-28 US claimed
CN-114072509-A Nucleobase editor with reduced off-target of deamination and method of modifying nucleobase target sequence using same 比姆医疗股份有限公司 2022-02-18 CN claimed
EP-1987035-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2008-11-05 EP claimed
WO-2007093515-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN LA-ROCHE AG (CH) 2007-08-23 WO claimed
US-20070191406-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2007-08-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191406-A1 Heterocyclic antiviral compounds CCR5, CX3CR1, CXCR1 POLB 2278/4885ALDH1A1 2289/4885HTT 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.